AstraZeneca’s Covid-19 Antibody Treatment Failed To Prevent Symptoms In Exposed Individuals The monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.